Deep Genomic Sequencing of Bladder Urothelial Carcinoma in Southern Chinese Patients: A Single-Center Study

Dong-Yang Li,Fei Yang,Wei-Qiang Liao,Xiang-Fu Zhou,Wen-Biao Li,Jia-Rong Cai,Bo-Long Liu,Yun Luo,Hai-Lun Zhan
DOI: https://doi.org/10.3389/fonc.2021.538927
IF: 4.7
2021-05-14
Frontiers in Oncology
Abstract:Objective Bladder urothelial carcinoma (BUC) is a common urological malignancy with molecular heterogeneity. However, the genetic feature of Chinese BUC patients is still not well-identified. Methods We performed deep sequencing by a large panel (450 genes) on 22 BUC samples and using matched normal bladder tissue as control. Genomic alterations (GAs), pathways and Tumor Mutation Burden (TMB) were investigated. Results The frequencies of GAs ( TERT , 54.5%; CREBBP , 27.3%; GATA3 , 22.7%; BRAF , 18.2%; TEK , 18.2% and GLI1 , 18.2%) were significantly higher in Chinese than Western BUC patients. Other GAs’ frequencies were in accordance with previous study ( TP53 , 50.0%; KDM6A , 31.8%; KMT2D , 22.7%; etc.). Besides, we detected gene amplification in ERBB2, FRS2, FAS , etc. The gene fusion/rearrangement took place in the chromosome 11, 12, 14, 17, 19, 22, and Y. Other than cell cycle and PI3K-AKT-mTOR, mutated genes were more associated with the transcription factor, chromatin modification signaling pathways. Interestingly, the TMB value was significantly higher in the BUC patients at stages T1–T2 than T3–T4 ( P = 0.025). Conclusion Deep genomic sequencing of BUC can provide new clues on the unique GAs of Chinese patients and assist in therapeutic decision.
oncology
What problem does this paper attempt to address?